title: Aromatase inhibitors in the treatment of bladder endometriosis.
abstract: BACKGROUND
  Aromatase inhibitors have recently been proposed for the treatment of endometriosis; however, no previous study examined the effects of these agents on pain and urinary symptoms of premenopausal women with bladder endometriosis.
  
  
  METHODS
  Two premenopausal patients with bladder endometriosis were treated with letrozole (2.5 mg/day), norethisterone acetate (2.5 mg/day), elemental calcium and vitamin D3 for 6 months. The double-drug regimen quickly improved pain and urinary symptoms in both patients. One patient had no significant adverse effect and continued the therapy for 14 months. The other patient developed myalgia and severe arthralgia; pain and urinary symptoms recurred few months after the interruption of the 6-month treatment and the patient underwent laparoscopic partial cystectomy.
  
  
  CONCLUSIONS
  Aromatase inhibitors improve pain and urinary symptoms in patients with bladder endometriosis; however, severe side effects of treatment may occur. These agents should be administered only to patients who refuse surgery and fail to respond to other therapies.
authors.affiliation: Department of Obstetrics and Gynecology, San Martino Hospital and University of Genoa, Genoa, Italy. dr@simoneferrero.com
authors.forename: Simone
authors.initials: S
authors.lastname: Ferrero
authors.forename: Ennio
authors.initials: E
authors.lastname: Biscaldi
authors.forename: Pier
authors.initials: P
authors.lastname: Luigi Venturini
authors.forename: Valentino
authors.initials: V
authors.lastname: Remorgida
mesh_terms: D000328:Adult; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002118:Calcium / Q000009:adverse effects / Q000627:therapeutic use; D002762:Cholecalciferol / Q000009:adverse effects / Q000627:therapeutic use; D015653:Cystectomy / Q000379:methods; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D009640:Norethindrone / Q000009:adverse effects / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000601:surgery
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D002762:Cholecalciferol; D000077289:Letrozole; D002118:Calcium; D009640:Norethindrone